Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8(+) T cell activation in the presence of adjuvant temozolomide

In a two-stage phase II study, 24 patients with first diagnosis of glioblastoma (GBM) were treated with dendritic cell (DC) immunotherapy associated to standard radiochemotherapy with temozolomide (TMZ) followed by adjuvant TMZ. Three intradermal injections of mature DC loaded with autologous GBM ly...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncoimmunology
Auteurs principaux: Pellegatta, Serena, Eoli, Marica, Cuccarini, Valeria, Anghileri, Elena, Pollo, Bianca, Pessina, Sara, Frigerio, Simona, Servida, Maura, Cuppini, Lucia, Antozzi, Carlo, Cuzzubbo, Stefania, Corbetta, Cristina, Paterra, Rosina, Acerbi, Francesco, Ferroli, Paolo, DiMeco, Francesco, Fariselli, Laura, Parati, Eugenio A., Bruzzone, Maria Grazia, Finocchiaro, Gaetano
Format: Artigo
Langue:Inglês
Publié: Taylor & Francis 2018
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5889286/
https://ncbi.nlm.nih.gov/pubmed/29632727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1412901
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires